Latest & greatest articles for breast cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for breast cancer

1. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea. 6 N N Petrov Research Institute of Oncology, St Petersburg, Russia. 7 12 de Octubre University Hospital, Medical Oncology Department, Madrid, Spain. 8 National Center for Tumor Diseases, University Hospital, German Cancer Research Center, Heidelberg, Germany. 9 Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. 10 F Hoffmann-La Roche, Basel, Switzerland. 11 Roche Products, Welwyn Garden City, UK. 12 (...) , Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea. 6 N N Petrov Research Institute of Oncology, St Petersburg, Russia. 7 12 de Octubre University Hospital, Medical Oncology Department, Madrid, Spain. 8 National Center for Tumor Diseases, University Hospital, German Cancer Research Center, Heidelberg, Germany. 9 Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. 10 F Hoffmann-La Roche, Basel, Switzerland. 11 Roche Products, Welwyn Garden City, UK. 12

2020 EvidenceUpdates

2. Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial

Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several (...) for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation J Clin Oncol Actions . 2020 Apr 10;38(11):1186-1197. doi: 10.1200/JCO.19.01371. Epub 2020 Feb 21. Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial

2020 EvidenceUpdates

3. Tucatinib (Tukysa) - To treat advanced unresectable or metastatic HER2-positive breast cancer

Tucatinib (Tukysa) - To treat advanced unresectable or metastatic HER2-positive breast cancer Drug Approval Package: TUKYSA U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: TUKYSA Company: Seattle Genetics, Inc. Application Number: 213411 Approval Date: 04/17/2020 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF

2020 FDA - Drug Approval Package

4. Sacituzumab govitecan-hziy (Trodelvy) - To treat adult patients with metastatic triple-negative breast cancer

Sacituzumab govitecan-hziy (Trodelvy) - To treat adult patients with metastatic triple-negative breast cancer Drug Approval Package: TRODELVY U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: TRODELVY Company: Immunomedics, Inc Application Number: 761115 Approval Date: 04/22/2020 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application

2020 FDA - Drug Approval Package

5. Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer

to eradicate or reduce tumour size before surgery. NICE recommends pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer, with trastuzumab and chemotherapy, for locally advanced, inflammatory or early breast cancer at high risk of recurrence. The patient expert explained that when residual disease is found during surgery this is a disappointing outcome, and preventing the cancer returning is very important to patients. After surgery, adjuvant treatment is used to reduce the risk (...) for adjuvant treatment of HER2-positive early breast cancer (TA632) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 151 1 Recommendations Recommendations 1.1 Trastuzumab emtansine is recommended, within its marketing authorisation, as an option for the adjuvant treatment of human epidermal growth factor receptor 2 (HER2)-positive early breast cancer in adults who have residual invasive disease in the breast or lymph

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

6. Invasive breast cancer and breast cancer mortality after ductal carcinoma in situ in women attending for breast screening in England, 1988-2014: population based observational cohort study. Full Text available with Trip Pro

Invasive breast cancer and breast cancer mortality after ductal carcinoma in situ in women attending for breast screening in England, 1988-2014: population based observational cohort study. To evaluate the long term risks of invasive breast cancer and death from breast cancer after ductal carcinoma in situ (DCIS) diagnosed through breast screening.Population based observational cohort study.Data from the NHS Breast Screening Programme and the National Cancer Registration and Analysis (...) treatment (mastectomy, radiotherapy for women who had breast conserving surgery, and endocrine treatment in oestrogen receptor positive disease) and those with larger final surgical margins had lower rates of invasive breast cancer.To date, women with DCIS detected by screening have, on average, experienced higher long term risks of invasive breast cancer and death from breast cancer than women in the general population during a period of at least two decades after their diagnosis. More intensive

2020 BMJ

7. Trastuzumab (Herzuma) - Breast Cancer and Gastric Cancer

Trastuzumab (Herzuma) - Breast Cancer and Gastric Cancer Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1

2020 Health Canada - Drug and Health Product Register

8. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial Full Text available with Trip Pro

A, Coombes G, Sergenson N, Sin HJ, Folkerd E, Dowsett M, Bliss JM; SoFEA investigators. Johnston SR, et al. Lancet Oncol. 2013 Sep;14(10):989-98. doi: 10.1016/S1470-2045(13)70322-X. Epub 2013 Jul 29. Lancet Oncol. 2013. PMID: 23902874 Clinical Trial. Show more similar articles References Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61–70. - - Stemke-Hale K, Gonzalez-Angulo AM, Lluch A. An integrative genomic and proteomic analysis of PIK3CA, PTEN (...) Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial Fulvestrant Plus Capivasertib Versus Placebo After Relapse or Progression on an Aromatase Inhibitor in Metastatic, Oestrogen Receptor-Positive Breast Cancer (FAKTION): A Multicentre, Randomised, Controlled, Phase 2 Trial - PubMed This site needs JavaScript to work properly

2020 EvidenceUpdates

9. Management of Hereditary Breast Cancer

[online only] 1 for more details of the literature search). Articles from the search were included if they reported data on outcomes of local therapy (therapeutic or prophylactic mastectomy, nipple-sparing mastectomy, RT) among women with newly diagnosed nonmetastatic or advanced breast cancer and a high- or moderate-penetrance germline mutation. Disease outcomes considered in the studies included in the literature were ipsilateral events, including true recurrences and new primary tumors, survival (...) short to evaluate lifetime risk. CLINICAL QUESTION 2 What is the appropriate surgical management of the index malignancy for women with newly diagnosed nonmetastatic breast cancer who have a selected moderate-penetrance mutation? Recommendation 2.1 For women with newly diagnosed breast cancer who have a mutation in a moderate-penetrance breast cancer gene, mutation status alone should not determine local therapy decisions for the index tumor or CRRM (Type: formal consensus; Evidence quality: low

2020 American Society of Clinical Oncology Guidelines

10. Management of Male Breast Cancer

receptor–positive breast cancer who are candidates for adjuvant endocrine therapy should be offered tamoxifen for an initial duration of five years; those with a contraindication to tamoxifen may be offered a gonadotropin-releasing hormone agonist/antagonist plus aromatase inhibitor. Men who have completed five years of tamoxifen, have tolerated therapy, and still have a high risk of recurrence may be offered an additional five years of therapy. Men with early-stage disease should not be treated (...) with bone-modifying agents to prevent recurrence, but could still receive these agents to prevent or treat osteoporosis. Men with advanced or metastatic disease should be offered endocrine therapy as first-line therapy, except in cases of visceral crisis or rapidly progressive disease. Targeted systemic therapy may be used to treat advanced or metastatic cancer using the same indications and combinations offered to women. Ipsilateral annual mammogram should be offered to men with a history of breast

2020 American Society of Clinical Oncology Guidelines

11. NAPBC Recommendations for Prioritization, Treatment and Triage of Breast Cancer Patients During the COVID-19 Pandemic

dose. Adjust boost as follows: No boost in original treatment plan: Add boost 2.5 Gy x 4 Boost in original treatment plan: consider additional 2.5 Gy fraction to boost PTV total 12.5 Gy ** BC, breast cancer; BCT, breast conserving therapy; ER, estrogen receptor; Gy; gray; HER2, human epidermal growth factor receptor 2; HF, hypofractionated; IMN, internal mammary node;LVI, lymphovascular invasion; NAC, neoadjuvant chemotherapy; PTV, planning tumor volume; PMRT, postmastectomy radiation therapy; PNI (...) the increased risk of adverse events. Dose reductions can minimize treatment-related toxicities. CDK4/6 inhibitors as first/second-line treatment offer clinical advantage, but may be delayed if the likelihood of tumor control is high with endocrine therapy alone (first line, no prior endocrine treatment, no visceral disease). 35 Dose reduction of palbociclib does not diminish efficacy. 36,37 High Risk Lesions and Pre-Invasive BC High-risk lesions such as atypical hyperplasia and lobular carcinoma in-situ

2020 American Society for Radiation Oncology

12. Relationship between volumes of services and quality of treatment outcome in the surgical treatment of breast cancer - rapid report

), proliferation rate (Ki-67 index), and spread in the lymph nodes, the tumour’s hormone receptor status, and completeness of resection in case of surgery (R0 resection) [13, 14, 17]. Surgical treatment of mammary carcinoma In 2014, suspected breast cancer resulted in 74 224 surgical procedures being performed at 817 German hospitals [9]. The surgical treatment of mammary carcinoma can be generally classified as breast-conserving surgery versus mastectomy. The choice of therapeutic procedure depends (...) - invasive mammary carcinoma and is chosen by about 60–70% of female patients [13]. It takes the form of either tumourectomy, segmentectomy, or quadrantectomy. The goal is complete tumour removal. Breast-conserving therapy with subsequent radiotherapy is equivalent to Extract of rapid report V18-05 Version 1.0 Relationship between volume and quality in breast cancer surgery 13 January 2020 Institute for Quality and Efficiency in Health Care (IQWiG) - 3 - mastectomy in terms of survival figures [19-21

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

13. Early Breast Cancer

conser- vative surgery is feasible and accurate for staging the axilla. Lobular neoplasia [formerly called lobular carcinoma in situ (LCIS)], unlike DCIS, is considered a non-obligate precursor to invasive cancer. It is regarded as a risk factor for future development of invasive cancer in both breasts [relative risk (RR): 5.4–12] and does not require active treatment. The pleomorphic variant of lobular neoplasia may behave similarly to DCIS and should be treated accordingly, after multidisciplin (...) the individual’s recurrence risk and potentially predict the bene?t of ChT in general [I, A] [19, 126], albeit not for specif- ic cytotoxic agents. Genomic tests are not recommended for patients with: • clinicopathological low-risk tumours (pT1a, pT1b, G1, ER high, pN0); and/or • patients with comorbid health conditions who are not candi- dates for adjuvant ChT; and/or • special types of luminal-like breast cancer such as low-grade encapsulated papillary carcinoma and solid papillary carcin- oma (which should

2020 European Society for Medical Oncology

14. Risk of breast cancer before and after rheumatoid arthritis, and the impact of hormonal factors Full Text available with Trip Pro

Risk of breast cancer before and after rheumatoid arthritis, and the impact of hormonal factors Risk of Breast Cancer Before and After Rheumatoid Arthritis, and the Impact of Hormonal Factors - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health U.S (...) Permalink Copy Page navigation Ann Rheum Dis Actions . 2020 Mar 11;annrheumdis-2019-216756. doi: 10.1136/annrheumdis-2019-216756. Online ahead of print. Risk of Breast Cancer Before and After Rheumatoid Arthritis, and the Impact of Hormonal Factors , , , Affiliations Expand Affiliations 1 Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden hjalmar.wadstrom@ki.se. 2 Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet

2020 EvidenceUpdates

15. Continuation of Annual Screening Mammography and Breast Cancer Mortality in Women Older Than 70 Years. (Abstract)

Continuation of Annual Screening Mammography and Breast Cancer Mortality in Women Older Than 70 Years. Randomized trials have shown that initiating breast cancer screening between ages 50 and 69 years and continuing it for 10 years decreases breast cancer mortality. However, no trials have studied whether or when women can safely stop screening mammography. An estimated 52% of women aged 75 years or older undergo screening mammography in the United States.To estimate the effect of breast cancer (...) screening on breast cancer mortality in Medicare beneficiaries aged 70 to 84 years.Large-scale, population-based, observational study of 2 screening strategies: continuing annual mammography, and stopping screening.U.S. Medicare program, 2000 to 2008.1 058 013 beneficiaries aged 70 to 84 years who had a life expectancy of at least 10 years, had no previous breast cancer diagnosis, and underwent screening mammography.Eight-year breast cancer mortality, incidence, and treatments, plus the positive

2020 Annals of Internal Medicine

16. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. (Abstract)

Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. The development and approval of cyclin-dependent kinase (CDK) 4 and 6 inhibitors for hormone receptor-positive and human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer represents a major milestone in cancer therapeutics. Three different oral CDK4/6 inhibitors, palbociclib, ribociclib, and abemaciclib, have significantly improved progression-free (...) inhibitors, including cell cycle alterations and activation of upstream tyrosine kinase receptors. A number of clinical trials are exploring several important questions regarding treatment sequencing, combinatorial strategies, and the use of CDK4/6 inhibitors in the adjuvant and neoadjuvant settings, thereby further expanding and refining the clinical application of CDK4/6 inhibitors for patients with breast cancer.Copyright © 2020 Elsevier Ltd. All rights reserved.

2020 Lancet

17. Somatic tumour gene testing for the diagnosis of renal cell carcinoma, hydatidiform moles, granulosa cell ovarian tumour, salivary gland tumours, and secretory carcinoma of the breast

, as requested by a specialist or consultant physician, for the characterisation of MALM2 gene rearrangement. Maximum one test per lifetime Fee: $340 XXXXX-17 Analysis of tumour tissue from a patient with clinical or laboratory evidence, including morphological features, of mammary analogue secretory carcinoma of the salivary gland, as requested by a specialist or consultant physician, for the characterisation of ETV6-NTRK3 gene rearrangement. Maximum one test per lifetime Fee: $340 XXXXX-18 Analysis (...) or mammary analogue secretory carcinoma (MASC) of salivary glands. Fee: $454 each OR In the assessment of malignant salivary gland tumours, identification of: • MALM2 gene status for the diagnosis of mucoepidermoid carcinoma AND/OR • ETV6-NTRK3 gene status for the diagnosis of analogue secretory carcinoma AND/OR • EWSR1 gene status for the diagnosis of hyalinising clear cell carcinoma. Fee: $454 (for each) OR Identification of TFE3 or TFEB gene rearrangement in the assessment of renal cell carcinoma. Fee

2020 Medical Services Advisory Committee

18. Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer

-expression-profiling-tests-for-early-stage-invasive-breast-cancer March 2020 Ontario Health Technology Assessment Series; Vol. 20: No. 10, pp. 1–234, March 2020 3 ABSTRACT Background Breast cancer is a disease in which cells in the breast grow out of control. They often form a tumour that may be seen on an x-ray or felt as a lump. Gene expression profiling (GEP) tests are intended to help predict the risk of metastasis (spread of the cancer to other parts of the body) and to identify people who will most (...) and the experiences, preferences, and values of people with early-stage invasive breast cancer. BACKGROUND Health Condition Breast cancer is a disease in which cells in the breast grow out of control, eventually forming a tumour. Environmental, lifestyle, and genetic factors influence a person’s risk of developing breast cancer. These risk factors may include obesity, physical inactivity, alcohol consumption, age, hormone replacement therapy, dense breasts, genetic mutation, and a personal and/or family history

2020 Health Quality Ontario

19. Similar Breast Cancer Risk in Women Older Than 65 Years Initiating Glargine, Detemir, and NPH Insulins

Similar Breast Cancer Risk in Women Older Than 65 Years Initiating Glargine, Detemir, and NPH Insulins Similar Breast Cancer Risk in Women Older Than 65 Years Initiating Glargine, Detemir, and NPH Insulins - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes (...) to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Diabetes Care Actions 2020 Feb 19 [Online ahead of print] Similar Breast Cancer Risk in Women Older Than 65 Years Initiating Glargine, Detemir, and NPH Insulins , , , , , , , , , , Affiliations Expand Affiliations 1 Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver

2020 EvidenceUpdates

20. Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221)

Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221) Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221) - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard (...) collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation J Clin Oncol Actions , 38 (8), 804-814 2020 Mar 10 Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221

2020 EvidenceUpdates